Dr Michaels(R) product family (also branded as Soratinex(R)) versus Methylprednisolone aceponate - a comparative study of the effectiveness for the treatment of plaque psoriasis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F16%3A10375020" target="_blank" >RIV/00216208:11130/16:10375020 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Dr Michaels(R) product family (also branded as Soratinex(R)) versus Methylprednisolone aceponate - a comparative study of the effectiveness for the treatment of plaque psoriasis
Popis výsledku v původním jazyce
As one of the most common dermatologic chronic-recurrent disease, variable therapeutic options are available today for management of psoriasis. Although topical high potency corticosteroids, alone or in association with salicylic acid or vitamin D analogues, are still considered the best treatment, they do not seem to possess the capability for a long-term control of the disease or prevent recurrences, as their side effects are major contraindications for continuative use. The aim of this study was to investigate whether Dr. Michaels(R) product family is comparable to methylprednisolone aceponate (MPA) as a viable alternative treatment option for the treatment and management of stable chronic plaque psoriasis. Thirty adults (13 male, 17 female, mean age 40 years) with mild to severe stable chronic plaque psoriasis, were included in the study. Patients were advised to treat the lesions of the two sides of their body (left and right) with two different unknown modalities for 8 weeks; the pack of Dr. Michaels(R) products on the left side (consisting of a cleansing gel, an ointment and a skin conditioner) and a placebo pack on the right side, consisting of a cleansing gel, methylprednisolone ointment and a placebo conditioner. Assessment was done using the Psoriasis Activity Severity Index (PASI) scores before treatment and after 2, 4, 6 and 8 weeks. The results achieved with the Dr. Michaels(R) (Soratinex(R)) product family for the treatment of chronic plaque psoriasis were better than the results achieved with methylprednisolone aceponate (MPA), even though quicker resolution was achieved with the steroid with 45% of patients achieving resolution within 8-10 days in comparison to 5-6 weeks in the Dr. Michaels(R) (Soratinex(R)) group. Before therapy, the mean PASI score of the LHS in Dr. Michaels(R) (Soratinex(R)) group was 13.8+-4.1 SD and 14.2+-4.2 SD in the RHS methylprednisolone aceponate (MPA) group. After 8 weeks of treatment 62% of the Dr. Michaels(R) (Soratinex(R)) group had achieved resolution whilst in the methylprednisolone aceponate (MPA) group, the figure remained at 45%. The mean PASI score after 8 weeks of treatment was calculated and in the LHS Dr. Michaels(R) (Soratinex(R)) group it was 2.8+-1.6 SD and 6.8+-2.4 SD in the RHS methylprednisolone aceponate group. In the RHS -methylprednisolone aceponate (MPA) group, 22% of patients failed to respond to the treatment in comparison to 6% in the LHS Dr. Michaels(R) (Soratinex(R)) group. Based on the results of this study, Dr. Michaels(R) products are a more effective treatment option, with insignificant side effects, compared to local treatment with methylprednisolone aceponate (MPA).
Název v anglickém jazyce
Dr Michaels(R) product family (also branded as Soratinex(R)) versus Methylprednisolone aceponate - a comparative study of the effectiveness for the treatment of plaque psoriasis
Popis výsledku anglicky
As one of the most common dermatologic chronic-recurrent disease, variable therapeutic options are available today for management of psoriasis. Although topical high potency corticosteroids, alone or in association with salicylic acid or vitamin D analogues, are still considered the best treatment, they do not seem to possess the capability for a long-term control of the disease or prevent recurrences, as their side effects are major contraindications for continuative use. The aim of this study was to investigate whether Dr. Michaels(R) product family is comparable to methylprednisolone aceponate (MPA) as a viable alternative treatment option for the treatment and management of stable chronic plaque psoriasis. Thirty adults (13 male, 17 female, mean age 40 years) with mild to severe stable chronic plaque psoriasis, were included in the study. Patients were advised to treat the lesions of the two sides of their body (left and right) with two different unknown modalities for 8 weeks; the pack of Dr. Michaels(R) products on the left side (consisting of a cleansing gel, an ointment and a skin conditioner) and a placebo pack on the right side, consisting of a cleansing gel, methylprednisolone ointment and a placebo conditioner. Assessment was done using the Psoriasis Activity Severity Index (PASI) scores before treatment and after 2, 4, 6 and 8 weeks. The results achieved with the Dr. Michaels(R) (Soratinex(R)) product family for the treatment of chronic plaque psoriasis were better than the results achieved with methylprednisolone aceponate (MPA), even though quicker resolution was achieved with the steroid with 45% of patients achieving resolution within 8-10 days in comparison to 5-6 weeks in the Dr. Michaels(R) (Soratinex(R)) group. Before therapy, the mean PASI score of the LHS in Dr. Michaels(R) (Soratinex(R)) group was 13.8+-4.1 SD and 14.2+-4.2 SD in the RHS methylprednisolone aceponate (MPA) group. After 8 weeks of treatment 62% of the Dr. Michaels(R) (Soratinex(R)) group had achieved resolution whilst in the methylprednisolone aceponate (MPA) group, the figure remained at 45%. The mean PASI score after 8 weeks of treatment was calculated and in the LHS Dr. Michaels(R) (Soratinex(R)) group it was 2.8+-1.6 SD and 6.8+-2.4 SD in the RHS methylprednisolone aceponate group. In the RHS -methylprednisolone aceponate (MPA) group, 22% of patients failed to respond to the treatment in comparison to 6% in the LHS Dr. Michaels(R) (Soratinex(R)) group. Based on the results of this study, Dr. Michaels(R) products are a more effective treatment option, with insignificant side effects, compared to local treatment with methylprednisolone aceponate (MPA).
Klasifikace
Druh
J<sub>SC</sub> - Článek v periodiku v databázi SCOPUS
CEP obor
—
OECD FORD obor
30216 - Dermatology and venereal diseases
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Biological Regulators and Homeostatic Agents
ISSN
0393-974X
e-ISSN
—
Svazek periodika
30
Číslo periodika v rámci svazku
2 Suppl 3
Stát vydavatele periodika
IT - Italská republika
Počet stran výsledku
5
Strana od-do
77-81
Kód UT WoS článku
—
EID výsledku v databázi Scopus
2-s2.0-85019795998